Mesoblast Gets FDA Nod for Extra Quality Check on Ryoncil
Mesoblast received FDA approval for a new TIBA assay to check strength and stability of every commercial Ryoncil batch as manufacturing scales.
/ 2 items
Mesoblast received FDA approval for a new TIBA assay to check strength and stability of every commercial Ryoncil batch as manufacturing scales.
Mesoblast completes treatment of 350 patients in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain due to degenerative disc disease. Results expected mid-2027.